-+ 0.00%
-+ 0.00%
-+ 0.00%
As star drugs such as simeglutide and tirpotide continue to refresh the market's perception of the effects of GLP-1 drugs in lowering sugar and weight loss, and innovative domestic pharmaceutical companies are also stepping up this circuit one after another, there seems to be no shortage of good drugs in the GLP-1 market. However, on the other side of the continued expansion of the market, the phenomenon of some patients discontinuing medication due to gastrointestinal adverse reactions, treatment costs, etc., still exists. For type 2 diabetics who need long-term blood sugar control, drugs not only need to be effective, but also need to balance tolerability, ease of treatment, and affordability of long-term medication. These clinical needs, which have not been fully met, are providing new development space for GLP-1 innovative drugs with differentiated characteristics.
Share
Listen to the news
As star drugs such as simeglutide and tirpotide continue to refresh the market's perception of the effects of GLP-1 drugs in lowering sugar and weight loss, and innovative domestic pharmaceutical companies are also stepping up this circuit one after another, there seems to be no shortage of good drugs in the GLP-1 market. However, on the other side of the continued expansion of the market, the phenomenon of some patients discontinuing medication due to gastrointestinal adverse reactions, treatment costs, etc., still exists. For type 2 diabetics who need long-term blood sugar control, drugs not only need to be effective, but also need to balance tolerability, ease of treatment, and affordability of long-term medication. These clinical needs, which have not been fully met, are providing new development space for GLP-1 innovative drugs with differentiated characteristics.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending